← Leaderboards
Susanna Naggie
Duke University
$17,969,569
Attributed
$17,969,569
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.2M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,969,569 · 2
By mechanism
N01$17,969,569 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Emmanuel B Walter$22,544,318
- William J Steinbach$15,812,111
- Angeles Alvarez Secord$1,416,047
- Jeffrey None Crawford$10,066,024
- Brian T Fisher$7,185,446
Others in their field
Top investigators on “Investigation”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$681,473,477
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$448,008,305
- Judith S. Currier · University Of California Los Angeles$395,422,692
Research focus
InvestigationConduct Clinical TrialsResourcesVaccinesEvaluationDesignContractsNamed GroupRouteInfectious Disease TreatmentAdultCoccidioidomycosisPhase Iv Clinical TrialsPneumoniaCommunitiesAntifungal AgentsAntimicrobial ResistanceCommunicable DiseasesCoccidioides ImmitisCoccidioides PosadasiiNational Institute Of Allergy And Infectious DiseaseOperationPreventionNew Agents
Grant awards (11)
Early Phase Clinical Trial Units (EPCTU)$193,337
N01 · FY2025 · AI · contact PI
Task A: Early Phase Clinical Trial Units (EPCTU)$191,600
N01 · FY2024 · AI · contact PI
Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia$93,126
N01 · FY2024 · AI · contact PI
Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia$668,565
N01 · FY2020 · AI · contact PI
Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia$9,208,909
N01 · FY2019 · AI · contact PI
Vaccine and Treatment Evaluation Units: Concept and Protocol Development$103,557
N01 · FY2018 · AI · contact PI
Vaccine and Treatment Evaluation Units: Concept and Protocol Development$128,378
N01 · FY2017 · AI · contact PI
Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia - VTEU$1,674,270
N01 · FY2016 · AI · contact PI
Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia - VTEU$364,065
N01 · FY2016 · AI · contact PI
Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia - VTEU$5,057,627
N01 · FY2015 · AI · contact PI
Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis Pneumonia - VTEU$286,135
N01 · FY2015 · AI · contact PI